Spinal Cord Injury (SCI) Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies – AbbVie, StemCyte, Kringle, Nipro Corporation, ReNetX Bio, and Others

Spinal Cord Injury (SCI) Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, StemCyte, Kringle, Nipro Corporation, ReNetX Bio, and Others
Delveinsight Business Research LLP
As per DelveInsight, the Spinal Cord Injury Therapeutics Market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world. Extensive research and development (R&D) activities of pharmaceutical companies for developing therapies for SCI will also significantly impact the market growth.

DelveInsight’s “Spinal Cord Injury (SCI) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinal Cord Injury market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Spinal Cord Injury market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Spinal Cord Injury (SCI): An Overview

Spinal Cord Injury (SCI) is a devastating event with sudden onset of motor and sensory dysfunction. Damage to autonomic neurons at and below the level of injury leads to bowel, bladder, and sexual functional loss. The prevalence of this trauma was formerly found primarily in young patients due to high-energy accidents and contact sports. However, cervical canal stenosis is increasingly found in elderly patients with the progress of our aging society and the susceptibility of elderly patients to easily injure their spinal cord from a fall.

SCI is categorized into traumatic and non-traumatic based on etiology. Traumatic Spinal cord injuries are most often the result of vehicle accidents, followed closely by falls. Non-traumatic spinal cord injury causes may include cancer and osteoporosis, spinal tumors, multiple sclerosis, inflammation of the spinal cord, arthritis, spinal stenosis, and blood loss.

Spinal Cord Injury Market Key Facts

  • The total prevalent population of Spinal cord injury (SCI) in the 7MM was 652,500+ in 2017.

  • The total prevalent cases of Spinal Cord Injury (SCI) were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.

  • According to the analysts at Delveinsight, the highest prevalent cases of this disease were observed in the United States, which accounted for 294,000 cases in 2017.

  • In 2017, the incident population of Spinal Cord Injury in Japan was found to be 5,000+ cases, and the prevalence was estimated to be 100,000 cases.

  • It is observed that the incidence of spinal cord injury (SCI) is approximately 54 cases per one million people in the United States, or about 17,810 new SCI cases each year. 

Spinal Cord Injury (SCI) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Spinal Cord Injury market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Spinal Cord Injury market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Spinal Cord Injury (SCI) Market Drivers:

  • Absence of therapies in the market

  • Increase in the affected population

  • Poor efficacy and side effects associated with current therapies

Spinal Cord Injury Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Spinal Cord Injury (SCI) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Cord Injury market or expected to get launched during the study period. The analysis covers the Spinal Cord Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinal Cord Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Spinal Cord Injury Market Will Evolve by 2032 @


Spinal Cord Injury (SCI) Therapeutics Analysis

There is no specific treatment for Spinal Cord Injury patients, and currently, surgical intervention and subsequent rehabilitation are the only options for SCI treatment. Although methylprednisolone is administered at the acute stage of injury, a consensus of its use has not yet been reached from the aspects of both safety and effectiveness.

Recent developments in stem cell research and numerous preclinical studies have demonstrated the effectiveness of neural precursor cell (NPC) transplantation in animal models of SCI.

Companies across the globe are working toward developing new treatment therapies for Spinal Cord Injury, but few companies have made it to the clinical stage of development.

Some of the key companies in the Spinal Cord Injury (SCI) Market include:

  • AbbVie

  • StemCyte

  • Kringle Pharma

  • Lineage Cell Therapeutics

  • Nipro Corporation

  • ReNetX Bio, Inc.

And many others. 

Spinal Cord Injury (SCI) Therapies covered in the report include:

  • MC001

  • AST-OPC1

  • KP-100IT

  • Elezanumab

  • Stemirac

  • AXER-204

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Spinal Cord Injury Competitive Intelligence Analysis

4. Spinal Cord Injury Market Overview at a Glance

5. Spinal Cord Injury Disease Background and Overview

6. Spinal Cord Injury Patient Journey

7. Spinal Cord Injury Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Spinal Cord Injury Treatment Algorithm, Current Treatment, and Medical Practices

9. Spinal Cord Injury Unmet Needs

10. Key Endpoints of Spinal Cord Injury Treatment

11. Spinal Cord Injury Marketed Products

12. Spinal Cord Injury Emerging Drugs and Latest Therapeutic Advances

13. Spinal Cord Injury Seven Major Market Analysis

14. Attribute Analysis

15. Spinal Cord Injury Market Outlook (In US, EU5, and Japan)

16. Spinal Cord Injury Access and Reimbursement Overview

17. KOL Views on the Spinal Cord Injury Market

18. Spinal Cord Injury Market Drivers

19. Spinal Cord Injury Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Hypereosinophilic Syndrome Market

“Hypereosinophilic Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/